

- McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. *Science* 2013;339:1563–1566.
- Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. *J Clin Oncol* 2013;31:1806–1814.
- Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. *Clin Trials* 2010;7:567–573.
- Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 1999;286:487–491.
- Wang L, McLeod HL, Weinsilboum RM. Genomics and drug response. *N Engl J Med* 2011;364:1144–1153.
- Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. *Blood* 2008;112:4808–4817.
- O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2003;348:994–1004.
- Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2006;355:2408–2417.
- Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. *N Engl J Med* 2007;357:39–51.
- Figueroa-Magalhaes MC, Jelovac D, Connolly RM, et al. Treatment of HER2-positive breast cancer. *Breast* 2014;23:128–136.
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;76:687–697.
- Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol* 2010;28:1254–1261.
- Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. *J Clin Oncol* 2009;27:1130–1136.
- Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? *J Clin Oncol* 2010;28:4769–4777.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507–2516.
- Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. *Oncogene* 2007;26:3279–3290.
- Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *J Clin Oncol* 2013;31:1767–1774.
- Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012;367:1694–1703.
- Muller PA, Vousden KH. p53 mutations in cancer. *Nat Cell Biol* 2013;15:2–8.
- Clarke PA, Workman P. Phosphatidylinositol-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. *J Clin Oncol* 2012;30:331–333.
- Ramaswamy S, Golub T. DNA microarrays in clinical oncology. *J Clin Oncol* 2002;20:1932–1941.
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351:2817–2826.
- Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 2006;24:3726–3734.
- Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat Med* 2012;18:382–384.
- Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol* 2014;32:579–586.
- Watters J, McLeod H. Cancer pharmacogenomics: current and future applications. *Biochim Biophys Acta* 2003;1603:99–111.
- Evans W, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 1999;286:487–491.
- Deenen MJ, Cats A, Beijnen H, et al. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. *Oncologist* 2011;16:820–834.
- Krynetski E, Evans W. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. *Oncogene* 2003;22:7403–7413.
- McLeod H, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. *Leukemia* 2000;14:567–572.
- Evans W, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. *J Clin Oncol* 2001;19:2293–2301.
- Relling M, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. *J Natl Cancer Inst* 1999;91:2001–2008.
- Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. *Clin Pharmacol Ther* 2013;93:324–325.
- Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clin Pharmacol Ther* 2013;94:640–645.
- McLeod H, Collie-Duguid ES, Vreken P, et al. Nomenclature for human DPYD alleles. *Pharmacogenetics* 1998;8:455–459.
- Wei X, Elizondo C, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. *Genomics* 1998;51:391–400.
- Ridge S, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. *Br J Cancer* 1998;77:497–500.
- Johnson M, Wang K, Diasio R. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. *Clin Cancer Res* 2002;8:768–774.
- Van Kuilenburg A, Meisma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. *Int J Cancer* 2002;101:253–258.
- Mürdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. *Clin Pharmacol Ther* 2011;89:708–717.
- Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. *J Pharmacol Exp Ther* 2004;310:1062–1075.
- Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. *Pharmacogenomics* 2002;3:229–243.
- Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther* 2012;91:321–326.
- Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. *JAMA* 2009;302:1429–1436.
- Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. *Clin Pharmacol Ther* 2014;95:216–227.
- Irvin WJ Jr, Walko CM, Weck KE, et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. *J Clin Oncol* 2011;29:3232–3239.